INTRODUCTION
The acute phase response (APR) is a generalized response of the organism to multiple disturbances of its physiological homeostasis. Inflammatory processes are the main causes for the initiation of these defense mechanisms (1) . As part of systemic inflammatory reactions, interleukin 6 (IL-6) regulates APR genes in liver cells including C-reactive protein (CRP), fibrinogen, serum amyloid A (SAA), α2-macroglobulin and albumin (2) (3) (4) . Elevated levels of IL-6 and liver APR genes that are a reflection of the inflammatory state have been reported in patients with acute coronary syndrome (5, 6 ).
IL-6 actions are mediated by a specific cell surface IL-6 receptor (IL-6R), an 80 kDa glycoprotein (gp80), and a signal-transducing molecule, glycoprotein gp130, which is also the signaling molecule for various IL-6 family cytokines (7, 8) . IL-6 binds to its cognate receptor and the IL-6/IL-6R forms a complex with a gp130 homodimer. Ligand-induced oligomerization of receptor subunits leads to activation and phosphorylation of signal transducer and activator of transcription 3 (STAT3) and of linker proteins, which propagate the signal to other pathways and cause activation of immediate early response genes, such as c-Jun (9) . STAT3 and c-Jun cooperatively activate APR gene transcription (10) (11) (12) and act in concert with various isoforms of the transcription factor CAAT-enhancer binding protein (C/EBP) (13) to up-regulate APR protein expression (14) (15) (16) (17) .
Fibrates are hypolipidemic drugs that efficiently normalize hypertriglyceridemia and hypercholesterolemia. In addition, fibrates may also lower fibrinogen and CRP plasma levels and affect other plasma APR proteins (18) (19) (20) . Fibrates exert their action via activation of the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARα). PPARα regulates transcription of target genes via binding of PPARα with its heterodimeric partner RXR to specific response elements. This pathway is mainly involved in the regulation of genes that play a role in lipid and lipoprotein metabolism and may, in large part, explain the normolipidemic by guest on October 1, 2017 http://www.jbc.org/ Downloaded from action of fibrates (21) . Furthermore, PPARα has been demonstrated to act as a negative regulator of genes involved in the inflammatory response by antagonizing the activity of transcription factors, such as NF-κB and AP-1, partly by direct interaction with proteins such as p65 and c-Jun (20, 22) . In line with these findings, impaired expression of PPARα has been found to sustain the inflammatory response (23) .
We previously showed that PPARα agonists attenuate the IL-6-induced expression of human fibrinogen genes in vitro in hepatocytes pre-treated for 4 hours with PPARα activators (24) . In the present work, we demonstrate that chronic in vivo treatment with the PPARα 
EXPERIMENTAL PROCEDURES

Animal studies
Animal studies were performed in compliance with European Community specifications regarding the use of laboratory animals. Experimental conditions have been described previously (19) . Briefly, male Sv/129 homozygous PPARα wild-type (+/+) and PPARα-deficient (-/-) mice (10 to 12 weeks of age) (a kind gift of Dr. Frank Gonzalez) were fed for 17 days with either a standard mouse chow or containing 0.2% (w/w) fenofibrate (3 mice per treatment). Mice were subjected to intra-peritoneal injection of IL-6 (0.5 µg/mice) or saline buffer 4 hours before sacrifice. Animals were killed by exsanguination under ether anesthesia. Livers were removed immediately, weighed, rinsed with 0.9% (w/v) NaCl, and subjected to nucleus isolation. For RNA analysis, a similar second experiment with longer IL-6 treatment (24 hours) was performed with 4 animals per group. For analysis of fenofibrate effect on gp130 protein at different time periods (1, 3, 7, 14 days), time course experiment was performed with either a standard chow or containing 0.2% (w/w) fenofibrate (3 mice per treatment). For immunoblotting, livers were homogenized in PBS containing proteinase inhibitors (PI) (Roche Diagnostics, Almere, The Netherlands), centrifuged (5 min, 13000 rpm) at 4°C, and soluble proteins were boiled in Laemmli electrophoresis buffer for immunoblot analysis.
Preparation of nuclei and run-on assays
Nuclei were prepared from fresh mice livers as described by Gorski et al. (25) . Transcription run-on assays were performed as described by Nevins et al. (26) . Equivalent amounts of labelled nuclear RNA were hybridized for 48 hours at 42°C to 1 µg of purified cDNA probes immobilized on Hybond C Extra filters (Amersham, Arlington Heights, IL). The following cDNAs were spotted: a mouse fibrinogen Aα-chain cDNA probe, a mouse fibrinogen Bβ-chain cDNA probe, a mouse fibrinogen γ-chain cDNA probe, a rat ACO cDNA probe, a mouse glyceraldehyde-3-phosphate deshydrogenase cDNA probe, a mouse serum amyloid A cDNA probe, a mouse haptoglobulin cDNA probe, a major urinary protein cDNA probe, and a human acidic ribosomal phosphoprotein 36B4 cDNA probe. After hybridization, filters were washed at room temperature for 10 minutes in 0.5 × SSC and 0.1% (w/v) sodium dodecyl sulfate (SDS), and twice for 30 minutes at 65°C, and subsequently exposed to an x-ray film (X-OMAT-AR, Eastman-Kodak, Rochester, NY).
RNA analysis
Total RNA extraction and Northern blot analysis were performed as described (27) Quantification of gp80 and gp130 mRNA expression was corrected using ribosomal protein 28S gene expression as a internal control.
Western blotting
For SDS-PAGE, samples were electrophoresed as described (24) . Proteins were blotted onto 
Clinical study
Mildly hyperlipidemic patients (n=38) received 250 mg fenofibrate (Knoll AG, Mannheim, Germany) per day for 4 weeks. After a 12 hour overnight fast, venous blood samples were taken under standardized conditions before and after 4 weeks of treatment with fenofibrate. Fibrinogen was determined by the Clauss method (28) . Plasminogen activity (%) was measured by a chromogenic assay (Chromogenix, Milano, Italy). For α2-macroglobulin, albumin and Creactive protein a nephelometric method was used (Beckman, Munich, Germany). Serum amyloid A was measured by a commercially available ELISA (Laboserv, Giessen, Germany).
Data was analyzed using the standard univariate repeated measures model (20) . A one-sided p value <0.05 was regarded as significant.
RESULTS
PPARα activation prevents IL-6-induced APR response at the mRNA level in vivo
To study the effect of chronic PPARα activation on IL-6-induced APR gene expression in vivo, we determined mRNA levels of APR genes in livers of wild-type and PPARα-deficient mice, untreated (control) or treated for 17 days with fenofibrate, and subsequently stimulated or not by IL-6 for 4 hours ( (29) and 36B4 which served as internal control. As expected, ACO mRNA levels were induced in fibrate-treated wild-type but not in PPARα-deficient mice ( Fig.   1 ). 36B4 mRNA levels remained constant under all conditions. Basal mRNA levels of the fibrinogen α, β and γ genes coding for the three non-identical polypeptide chains, Aα, Bβ and γ, were decreased by fenofibrate treatment in wild type but not in PPARα-deficient mice (Fig. 1 ).
Wild-type mice stimulated with IL-6 responded with a strong induction of the mRNA expression of the three fibrinogen genes. Interestingly, this IL-6 effect was fully suppressed by fenofibrate treatment in wild-type mice, whereas IL-6 stimulated mRNA levels of the three fibrinogen genes was unaffected by fenofibrate treatment in PPARα-deficient mice.
To determine whether the suppressive effect of PPARα on IL-6-induced APR gene expression is global, the influence of fenofibrate on other positive as well as negative APR gene expression was also analyzed. In wild-type and PPARα-deficient mice, IL-6 treatment increased mRNA levels of the positive APR genes SAA and HG and decreased the negative APR gene MUP ( Fig. 1) . Fenofibrate treatment inhibited IL-6-stimulated mRNA expression of the SAA and HG genes in the livers of wild-type mice whereas, similar as for fibrinogen, no effect was observed in PPARα-deficient mice. Remarkably, the down-regulation of MUP by IL-6 was completely prevented by fenofibrate treatment in wild-type but not in PPARα-deficient mice ( Fig. 1 ). Together these results indicate that chronic PPARα activation has a global effect on the hepatic expression of both positive and negative acute phase genes in vivo.
To determine whether PPARα activation also delays IL-6 modulation of APR genes at a later time point, the effect of chronic fenofibrate treatment was examined on mRNA levels of APR genes in livers of wild-type mice (four mice per treatment) stimulated or not with IL-6 for 24 hours (Fig. 2) . Control and fenofibrate groups without IL-6 stimulation exhibit comparable effect as reported higher (Fig. 1) . Activation of all three fibrinogen genes by IL-6 was almost totally abolished after 24 hours IL-6 treatment, whereas activation of SAA and HG was still detectable at this time point and whereas MUP, mRNA expression partially recovered after 24 hours of IL-6 treatment ( Fig. 2) . Interestingly, fenofibrate treatment prevented the effects of IL-6 stimulation for 24 hours in a similar manner as after 4 hours of IL-6 stimulation. These results demonstrate that the systemic response to IL-6 treatment is not delayed but prevented upon PPARα activation in vivo.
Suppressive effect of PPARα on IL-6-induced APR occurs at the transcriptional level in vivo
To determine whether the effect of PPARα on APR gene expression occurs at the transcriptional level in vivo, nuclear run-on transcription assays were performed on nuclei prepared from livers of wild-type and PPARα-deficient mice, pretreated or not with fenofibrate, and stimulated or not with IL-6 for 4 hours (Fig. 3) . As expected, the transcription rate of ACO was enhanced in fenofibrate-treated wild-type mice but not in PPARα-deficient mice and IL-6 treatment slightly increased ACO transcription independent of the presence or absence of PPARα (Fig. 3A) . As negative control, GAPDH transcription levels remained constant under all conditions. Basal transcription of the fibrinogen α and γ genes and to a lesser extent of the fibrinogen β gene was decreased by fenofibrate treatment (Fig. 3A) . In wild-type mice the transcription rate of the three fibrinogen genes was strongly enhanced upon IL-6 stimulation, an effect which was fully abolished by fenofibrate treatment. As observed at the mRNA levels, the basal transcription rates of the three fibrinogen genes was elevated in PPARα-deficient mice compared to wild-type mice. The absence of effect of fenofibrate treatment in PPARα-deficient mice demonstrated that PPARα is required for fenofibrate inhibition of IL-6-mediated fibrinogen gene transcription in vivo.
The suppressive effect of PPARα on the IL-6-induced APR also occurs at the transcriptional level for both the positive (SAA and HG) and the negative APR gene (MUP) (Fig.   3B ). Again, the involvement of PPARα in the action of fenofibrate was demonstrated using PPARα-deficient mice in which fenofibrate had no effect on the transcriptional regulation of both positive and negative APR genes (Fig. 3B ). Together these results indicate that PPARα exerts its global effect on the hepatic expression of both positive and negative APR genes at the level of transcription.
PPARα represses the expression of IL-6 receptor complex components in vivo
The broad effect on positive and negative APR proteins prompted us to analyze whether PPARα acts at the level of upstream receptor proteins required for IL-6 signal transduction, i.e. gp80 and gp130. The levels of gp80 and gp130 mRNA were determined in livers of mice treated with fenofibrate for 17 days by quantitative RT-PCR. A marked decrease of both gp80 and gp130 mRNA expression was observed in wild-type mice upon fenofibrate treatment (Fig. 4A) . (Fig. 4A) . Next, the level of gp80 and gp130 proteins was analyzed by Western blot. Whereas the expression of gp80 was very weak and too low to be detectable by Western blot, the gp130 subunit was reduced in a PPARα-dependent fashion (Fig. 4B) . Results from a time course experiment with fenofibrate indicated that the protein levels of gp130 already slightly decreased after 3 days of treatment and strongly decreased on further prolonged treatment (Fig. 5) .
Finally, it was analyzed whether fenofibrate treatment also reduced gp130 protein levels in non-hepatic tissues, i.e. heart, kidney, muscle and spleen of mice treated with fenofibrate for two weeks. Whereas gp130 protein was expressed in all tissues tested (Fig. 6) , a downregulation was observed only in liver but not in the other tissues tested. Altogether, these findings demonstrate that PPARα activation decreases the expression of hepatic IL-6 receptor system proteins required for IL-6 signal transduction, which, in part, explains the global suppressive effect of fenofibrate on IL-6-mediated APR gene expression. Also, we identify the IL-6 receptor subunits gp80 and gp130 as two novel PPARα-regulated genes.
Activated PPARα lowers protein concentrations of transcription factors mediating the IL-6-induced APR in vivo
The gp130 subunit transduces the IL-6 signal to downstream transcription factors and mediates Tyr705-phosphorylation, which results in activation of STAT3 (7) and subsequent transcription of STAT3-regulated APR genes (30) . Recently, it has been reported that c-Jun and phosphorylated c-Jun enhance IL-6-mediated activation of transcription (11, 12) . We therefore (Fig. 7A) . However, phosphorylated-STAT3 levels were decreased in wild-type mice treated with fenofibrate but not in PPARα-deficient mice, which is in accordance with the observed PPARα-dependent down-regulation of the gp130 receptor subunit.
Fenofibrate-treatment only slightly reduced basal c-Jun levels in wild-type mice. However, a strong reduction of phosphorylated c-Jun levels was observed in wild-type mice exposed to fenofibrate. By contrast, this reduction was not observed in PPARα-deficient mice (Fig. 7A) .
The protein concentration of C/EBP transcription factors determines the transcriptional regulation of many IL-6 responsive APR genes (14) . C/EBPs are induced by IL-6 and act in concert with STAT3 and c-Jun to promote APR gene expression (13) . Interestingly, analysis of the effect of fenofibrate on C/EBP expression levels in wild-type and PPARα-deficient mice revealed that the basal protein expression levels of the isoforms C/EBPα, β and δ were markedly reduced in livers of wild-type mice treated for 17 days with fenofibrate ( 
Treatment with fenofibrate regulates the expression of positive and negative APR proteins in humans
positive and negative APR proteins in humans, plasma samples of patients with mild hyperlipidemia that had undergone a four-week fenofibrate treatment were analyzed before and after the treatment. The influence of fenofibrate on plasma concentrations of marker proteins that are related to the APR is summarized in Table 1 . Significantly reduced plasma concentrations were observed for the positive APR proteins fibrinogen, CRP, SAA, α2-macroglobulin, and plasminogen, while the negative APR protein albumin was elevated by fenofibrate treatment.
The data show that treatment with fenofibrate has a similar broad effect on the expression of positive and negative APR proteins in humans and underscore the clinical significance of our findings in mice. The global effect of PPARα on the expression of positive and negative APR gene expression suggested an upstream suppression of the IL-6 pathway. IL-6-induced APR genes share a common receptor system, consisting of gp80 and gp130, which initiates a signaling cascade leading to STAT3 activation by phosphorylation. In fenofibrate-treated wild-type mice, PPARα down-regulates mRNA expression levels of the IL-6R (gp80) by 70% and of the signal transducer gp130 by 60%. In line with this observation we found a PPARα-dependent reduced expression of gp130 protein and, accordingly, reduced levels of phosphorylated STAT3. All these effects were not observed in PPARα-deficient mice indicating that the down-regulation is PPARα-dependent thereby identifying gp80 and gp130 as two novel PPARα-regulated genes. Of note, propagation of the IL-6 signal to other pathways also requires a functional gp130 subunit (11, 12) and the PPARα-dependent down-regulation of gp130 may cause the observed reduced phosphorylation, i.e. activation, of c-Jun.
Our finding that PPARα can downregulate gp130 expression may also be of relevance for other cytokines of the IL-6 family since IL-6, IL-11, leukemia inhibitory factor (LIF), oncostatin M, ciliary neurotrophic factor (CNTF) and cardiotrophin (CT)-1, all share the gp130 receptor for signal transduction (8, 11) . Not unexpectedly for such a central receptor, the gp130 gene knockout is lethal, whereas mice deficient in one of the above cytokines display only relatively mild defects (35) . Nevertheless, we found that PPARα-dependent repression of gp130 occurs in liver but not in heart, kidney, muscle or spleen when PPARα is activated by fenofibrate. Depending on the tissue-specificity of PPARα activation and properties of PPARα ligands, PPARα may influence processes triggered by the above cytokines such as haematopoiesis, leukocyte proliferation, blastocyst implantation, osteoclast development (7). Down-regulation of the gp80/gp130 receptor system may not fully explain the broad and potent activity of PPARα on APR gene regulation for two mains reasons. First, since complete abolishment of gp130 protein expression only occurs after PPARα activation for at least 7 days and second, since the promoter regions of APR genes display a high degree of divergence with respect to the types and number of response elements. C/EBPs are responsible for immediate and maintained activation of transcription of the IL-6-induced APR and APR gene transcription is related to the concentrations of C/EBPs present in the cell (14) (15) (16) . It has been reported that genetic ablation of a single C/EBP isoforms does not lead to the complete abolishment of the APR (36) and it is suggested that lack of one particular C/EBP isoform is compensated by the other C/EBP isoforms. Our results show that the basal cellular protein concentrations of C/EBPα, β and δ isoforms are PPARα-dependently decreased in wild-type mice by fenofibrate treatment.
The observed reduction of all three C/EBP isoforms thus prevents any compensatory mechanism in these mice. In PPARα-deficient mice, the basal C/EBPα, β and δ protein levels were comparable to the basal levels in wild-type mice and were, by contrast, not downregulated by fenofibrate treatment. This PPARα-dependent downregulation of C/EBPα and δ is supported by data from Takata It may be speculated that the reduced gp130 activity and thus reduced STAT3 activation in wildtype mice treated with fenofibrate may contribute to a downregulation of C/EBPs in liver.
In humans, we found that fenofibrate treatment reduced the plasma concentrations of the positive APR proteins fibrinogen and CRP, which has also been observed for other PPARα-activators, i.e. bezafibrate (18) and ciprofibrate (38). In this study we demonstrate that treatment with fenofibrate has a much broader effect on plasma levels of APR proteins in humans and causes downregulation of SAA, α2-macroglobulin, and plasminogen. We show for the first time that the plasma concentration of a negative APR protein, albumin, is increased in humans. This is in accordance with the transcriptional changes of the respective murine genes in fenofibratetreated mice and suggests a comparable suppressive effect of PPARα on acute phase gene transcription in mice and humans.
In conclusion, PPARα activation thus impairs the IL-6 signaling pathway in the liver at two levels, the level of membrane receptors and the level of transcription factors, together resulting in a potent suppression of the IL-6-stimulated APR gene expression. PPARα could be considered as a factor playing a determinant role in the control of hepatic inflammation at the molecular level and thus forms an attractive target to dampen deleterious effects of inflammation in liver. Mice were treated with 0.2% (w/w) fenofibrate (FF) or not (Cont) for two weeks. Western blot analysis of gp130 from proteins extracted from liver, heart, kidney, muscle and spleen. 
TABLES
